BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
GENERAL COMMENTS
The review is interesting and is timely. Mucin histochemistry is a tedious business and many reports are available to show that in practice. This difficulty arises from the fact that both protein core and glycosylation influence reactivity of the mucin. Even more, some antibodies recognize glycosylation specific glycotopes. This should be discussed in more detail. See e. The writing of this manuscript should be improved. The current version contains many typos and grammar mistakes. For example, "matthew" should be "Matthew" at the bottom of page 7, the web link in the second line on page on page 8 did not display properly, the subtitle "... and publication Bias" should be "... and publication bias". On page 10, "Nine studies evaluating ..." should be "Nine studies evaluated ...", and there were many similar issues like this.
Change "Begg's funnel plot" to "funnel plot" throughout this manuscript, because it was not initially proposed by Begg. See https://en.wikipedia.org/wiki/Funnel_plot.
The materials about assessing publication bias in the middle of page 8 were repeated in the middle of page 9. This is unnecessary. Also, cite Egger's paper (Egger et al., 1997, BMJ) when Egger's regression test is mentioned. Usually, for publication bias tests, P < 0.1 (not 0.05) is considered significant because their statistical power is often low.
In Figure 1 On page 12, "Egger's test P > 0.134". Why not present the exact P value?
VERSION 1 -AUTHOR RESPONSE
Response to the reviewers Reviewer 1# Comment 1: As there are many candidate markers for CCA reported, the authors should provide the rational why MUC1 was selected as the marker for CCA in this study.
Response: : Thank you very much for asking this question. As previous published literatures, many candidate markers for CCA such as IL6 (interleukin6), serum cytokeratin19 fragments, mucin2~6, serotonin, tumor type M2 pyruvate kinase, etc. involved in this system, However, the clinical applicability of most existing markers is limited due to a lack of adequate sensitivity and specificity compared with CA19-9, the most used serum tumour marker for CA19-9. Furthermore, the vast majority of existing markers for CAA reported by handful research with a limited number of participants.
Recently (2):218-228) in their publications included a large number of participants reported that Wisteria floribunda agglutinin-sialylated mucin 1 (WFA-MUC1) had a high diagnostic capability compared with CA19-9 in discriminating CCA from benign biliary disease, which is an encouraging thing for us. However, the various diagnostic capability has been reported by previous studies, the optimal diagnostic capability of WFA-MUC1 remains unclear as we described in the "Introduction Section" of our manuscript. As described above, that's the reason why we focused on MUC1 in this study. Response: Thanks for the suggestions. As suggested, we searched the GO classification system (http://www.pantherdb.org/) to found the Molecular Function (MF), Biological Process (BP) and Reactome Pathways of MUC1 in cancer, which was summarized in Table 4 .. Response: Sorry for the typo. We had corrected the typing errors caused by our carelessness in writing and provided the full words of each abbreviation at the first presentation.
Reviewer 2#
Comments: The review is interesting and is timely. Mucin histochemistry is a tedious business and many reports are available to show that in practice. This difficulty arises from the fact that both protein core and glycosylation influence reactivity of the mucin. Even more, some antibodies recognize glycosylation specific glycotopes. This should be discussed in more detail. See e. g.: Schumacher U, Adam E. Immunohistochemical detection of the MUC1 gene product in human cancers grown in scid mice. J Histochem Cytochem. 1998 Jan;46 (1) Table 2 showed, all included reports used WFA-MY.1E12 to detect the concentration of MUC1 in serum or bile, so the methodology of detecting the MUC1 in bile or serum was consistent as described in the "Method and Material" section of included studies.
It's a truth that the antibody is detecting the MUC1 in cancer tissue was not identical among the included studies, as Table 3 depicted. However, these antibodies were designed to identify the epitope of MUC1, not the glycan associated with MUC1. Due to the various criteria of positive or high expression of MUC1 in tissue, a further analysis cloud not be performed to determine which is better about the methodologies.
